Healthcare
Cue Biopharma Inc(CUE)
Live Price
Offline$27.86
-8.48% today
1Y Change
+14.89%
Window
Jun 27, 2025 โ Jun 25, 2026
- Market Cap
- $90.00M
- Revenue Growth
- +195.7%
- EPS Growth
- +61.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 27, 2025 โ Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cue Biopharma Inc (CUE) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $27.86 and up 14.9% across the available one-year price window (Jun 27, 2025 โ Jun 25, 2026). Baseline metrics include revenue growth of +195.7%, EPS growth of +61.1%, a dividend yield of 0.0%. What stands out right now is revenue +195.7%, EPS +61.1%, free cash flow +39.9% with operating margin -96.6% and ROIC -86.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CUE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+195.7% vs +7.6% peer median
Operating Margin
Below sector median
-96.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +195.7% and EPS at +61.1%, with operating margin around -96.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 30, 2026 | โ | +1.8% | -16.8% | +83.7% |
2026 Mar 16, 2026 | +111.1% | -12.8% | -14.7% | +40.4% |
2025 Nov 12, 2025 | +30.0% | -7.2% | -13.2% | -26.2% |
Benchmark Edge
CUE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CUE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CUE Max Drawdown
-80.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CUE and SPY.
Company Overview
Cue Biopharma Inc
NASDAQ
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutic biologics designed to selectively engage and modulate disease-specific T cells. The company's engineered biologics platform mimics nature's immune signals to expand and activate targeted immune cells, addressing both autoimmune diseases and cancer indications. Its primary pipeline includes CUE-401, a bifunctional molecule designed to induce regulatory T cells for autoimmune and inflammatory disease treatment; CUE-101, which combines T cell modulation with checkpoint inhibitor therapy for head and neck cancer; and CUE-501, targeting autoimmune diseases through anti-viral T cell-mediated B cell depletion. Cue Biopharma operates through strategic partnerships with pharmaceutical companies, generating non-dilutive funding to support clinical development. Founded in 2014 and headquartered in Boston, the company focuses on precision immunotherapy approaches that leverage the body's natural immune mechanisms to restore immune balance and treat serious diseases.
- Leadership
- Dr. Usman Azam M.D.
- Employees
- 41
- Street Address
- 40 Guest Street
- Mailing
- Boston, MA, 02135
- Region
- Boston, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.3
- Price/Book
- 4.8
Growth
- Revenue
- +195.7%
- EPS
- +61.1%
- Free Cash Flow
- +39.9%
Profitability
- Gross Margin
- 88.0%
- Operating Margin
- -96.6%
- Net Margin
- -96.9%
- ROE
- -165.2%
- ROIC
- -86.6%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 2.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.